回生口服液联合西医治疗对非小细胞肺癌免疫功能、肿瘤血管生成影响的Meta分析  

Effect of Huisheng Oral Liquid Combined with Western Medicine on Immune Function and Tumor Angiogenesis of Non-small Cell Lung Cancer:a Meta-analysis

作　　者：张金华 田园 杨晓萍[3] ZHANG Jin-hua;TIAN Yuan;YANG Xiao-ping(Department of Oncology,Jingmen First People’s Hospital,Jingmen 448000 Hubei,China;Center for Phenomics of Traditional Chinese Medicine,Traditional Chinese Medicine Hospital Affiliated to Southwest Medical University,Luzhou 646000 Sichuan,China;Internal Medicine of Traditional Chinese Medicine,Shanghai Seventh People’s Hospital,Shanghai 200003,China)

机构地区：[1]荆门市第一人民医院肿瘤科,湖北荆门448000 [2]西南医科大学附属中医医院中医药表型组学研究中心,四川泸州646000 [3]上海市第七人民医院中医内科,上海200003

出　　处：《中医肿瘤学杂志》2022年第2期61-68,共8页Journal of Oncology in Chinese Medicine

基　　金：上海市浦东新区卫生和计划生育委员会学科建设主攻课题计划(编号:PWZzk2017-01)。

摘　　要：目的系统评价回生口服液联合西医治疗对非小细胞肺癌免疫功能、肿瘤血管生成影响。方法计算机检索中国知网(CNKI)、中国学术期刊数据库(Wanfang Database)、中国生物医学文献数据库(CBM)、中文科技期刊数据库(VIP)、PubMed、Cochrane Library、Embase、Web of Science建库至2021年9月收录的回生口服液联合西医治疗对非小细胞肺癌免疫功能、肿瘤血管生成影响的随机对照试验文献。研究者对纳入文献进行资料提取和文献质量评价,采用RevMan5.3软件进行Meta分析。结果最终纳入9项随机对照试验研究,共739例患者,试验组375例,对照组364例。Meta分析结果显示:回生口服液组CD3+水平[MD=8.67,95%CI(7.31,10.02),P<0.001]、CD4+水平[MD=6.92,95%CI(5.81,8.03),P<0.001]、CD4+/CD8+水平[MD=0.35,95%CI(0.07,0.63),P=0.02]、IL-18升高值[MD=23.97,95%CI(2.22,45.71),P=0.03]均高于对照组,差异有统计学意义;CD8+水平低于对照组,且差异有统计学意义[MD=-2.78,95%CI(-3.35,-2.21),P<0.001];两组NK细胞百分比之间差异无统计学意义[MD=3.19,95%CI(-1.08,7.45),P=0.14]。回生口服液组MMP-9下降值大于对照组[MD=27.10,95%CI(6.82,47.39),P=0.009]差异有统计学意义;VEGF下降值大于对照组[SMD=3.75,95%CI(0.99,6.51),P=0.008]差异有统计学意义;两组IL-6水平之间差异无统计学意义[MD=-9.02,95%CI(-31.74,13.71),P=0.44];结论回生口服液可能通过提高CD3+、CD4+、CD4+/CD8+、IL-18水平,降低CD8+、MMP-9、血管内皮生长因子(vascular endothelial growth factor,VEGF)水平,增强非小细胞肺癌患者免疫功能、抑制肿瘤血管生成,但还需要更多高质量临床试验加以验证。Objective To systematically evaluate the effect of Huisheng Oral Liquid combined with western medicine on immune function and tumor angiogenesis of non-small cell lung cancer.Methods Literature about RCTs of effect of Huisheng Oral Liquid combined with western medicine on immune function and tumor angiogenesis of non-small cell lung cancer in CNKI,Wanfang Database,CBM,VIP,PubMed,CochraneLibrary,Embase,and Web of Science was retrieved by computer from the establishment of database to September 2021.Data extraction and quality evaluation were conducted for the included literature.Meta-analysis were performed using RevMan 5.3 sofware.Results 9 RCTs involving 739 patients were eventually included.There were 375 cases in trial group and 364 cases in control group.The results of Meta-analysis showed compared with control group,Huisheng oral liquid group could improve CD3+level[MD=8.67,95%CI(7.31,10.02),P<0.001],CD4+level[MD=6.92,95%CI(5.81,8.03),P<0.001],CD4+/CD8+level[MD=0.35,95%CI(0.07,0.63),P=0.02],IL-18 elevation value[MD=23.97,95%CI(2.22,45.71),P=0.03],reduce CD8+level[MD=-2.78,95%CI(-3.35,-2.21),P<0.001].There was no statistically significant difference between the two groups in the NK cell[MD=3.19,95%CI(-1.08,7.45),P=0.14].The decrease value of MMP-9 in Huisheng oral liquid group was greater than that in control group[MD=27.10,95%CI(6.82,47.39),P=0.009],The decrease value of VEGF in Huisheng oral liquid group was greater than that in control group[SMD=3.75,95%CI(0.99,6.51),P=0.008].There was no statistically significant difference between the two groups in the IL-6 level[MD=-9.02,95%CI(-31.74,13.71),P=0.44].Conclusion Huisheng oral liquid may improve the levels of CD3+,CD4+,CD4+/CD8+and IL-18,reduce the levels of CD8+,MMP-9 and VEGF,enhance the immune function of NSCLC patients and inhibit tumor angiogenesis,However,more high-quality clinical trials are needed to verify this.

关 键 词：回生口服液 非小细胞肺癌 免疫功能 肿瘤血管生成 META分析 

分 类 号：R730.52[医药卫生—肿瘤]